TY - JOUR
T1 - Update on heart failure, heart transplant, congenital heart disease, and clinical cardiology
AU - Comín, Josep
AU - Díaz-Molina, Beatriz
AU - Barón, Gonzalo
AU - Barrios, Vivencio
AU - Gómez-Doblas, Juan José
AU - Carrasco, José Ignacio
AU - Almenar, Luis
AU - Zunzunegui, José Luis
AU - Subirana, M. Teresa
PY - 2013/4/1
Y1 - 2013/4/1
N2 - In the year 2012, 3 scientific sections - heart failure and transplant, congenital heart disease, and clinical cardiology - are presented together in the same article. The most relevant development in the area of heart failure and transplantation is the 2012 publication of the European guidelines for heart failure. These describe new possibilities for some drugs (eplerenone and ivabradine); expand the criteria for resynchronization, ventricular assist, and peritoneal dialysis; and cover possibilities of percutaneous repair of the mitral valve (MitraClip®). The survival of children with hypoplastic left heart syndrome in congenital heart diseases has improved significantly. Instructions for percutaneous techniques and devices have been revised and modified for the treatment of atrial septal defects, ostium secundum, and ventricular septal defects. Hybrid procedures for addressing structural congenital heart defects have become more widespread. In the area of clinical cardiology studies have demonstrated that percutaneous prosthesis implantation has lower mortality than surgical implantation. Use of the CHA 2DS2-VASc criteria and of new anticoagulants (dabigatran, rivaroxaban and apixaban) is also recommended. In addition, the development of new sequencing techniques has enabled the analysis of multiple genes. © 2012 Sociedad Española de Cardiología. Published by Elsevier España, S.L. All rights reserved.
AB - In the year 2012, 3 scientific sections - heart failure and transplant, congenital heart disease, and clinical cardiology - are presented together in the same article. The most relevant development in the area of heart failure and transplantation is the 2012 publication of the European guidelines for heart failure. These describe new possibilities for some drugs (eplerenone and ivabradine); expand the criteria for resynchronization, ventricular assist, and peritoneal dialysis; and cover possibilities of percutaneous repair of the mitral valve (MitraClip®). The survival of children with hypoplastic left heart syndrome in congenital heart diseases has improved significantly. Instructions for percutaneous techniques and devices have been revised and modified for the treatment of atrial septal defects, ostium secundum, and ventricular septal defects. Hybrid procedures for addressing structural congenital heart defects have become more widespread. In the area of clinical cardiology studies have demonstrated that percutaneous prosthesis implantation has lower mortality than surgical implantation. Use of the CHA 2DS2-VASc criteria and of new anticoagulants (dabigatran, rivaroxaban and apixaban) is also recommended. In addition, the development of new sequencing techniques has enabled the analysis of multiple genes. © 2012 Sociedad Española de Cardiología. Published by Elsevier España, S.L. All rights reserved.
KW - Heart failure
KW - Heart transplant
KW - Clinic cardiology
KW - Congenital heart disease
UR - https://dialnet.unirioja.es/servlet/articulo?codigo=4209180
U2 - 10.1016/j.recesp.2012.10.022
DO - 10.1016/j.recesp.2012.10.022
M3 - Article
SN - 0300-8932
VL - 66
SP - 290
EP - 297
JO - Revista Espanola de Cardiologia
JF - Revista Espanola de Cardiologia
IS - 4
ER -